Talk:Methylphenidate

message: *Support These are adverse effects. In the common sense of the term an overdose is generally an acute event due to an overly large dose. Such a positioning is also fully compliant with WPMEDMOS. Abuse is listed as a blackbox warning which we generally list under adverse events. Doc James (talk · contribs · email) 06:51, 17 May 2019 (UTC)
replies: text: Dependence, although uncommon, can occur at therapeutic doses and the British National Formulary warns of withdrawal/discontinuation symptoms when stopping stimulants including dextroamphetamine and methylphenidate. Addiction does involve frequent exceeding of therapeutic doses but is not usually what is meant by the term overdose. The usual clinical and indeed lay meaning of overdose is when either someone accidentally significantly exceeds the prescribed dose or when a recreational user exceeds the dose needed to get high and experiences symptoms of toxicity. In summary, overdose refers to symptoms of acute toxicity from overdose beyond simple euphoria.--Literaturegeek | T@1k? 10:08, 18 May 2019 (UTC)
thread_title: Adverse effects section

message: *Support per the discussion section; however, given that I'm going to have to propose a change to the MOS:MED to address the underlying issue, I don't see the point of this RfC. The outcome will become moot once there's consensus for implementing an alternative layout for the addiction section in drug articles. Seppi333 (Insert 2¢) 07:47, 17 May 2019 (UTC)
thread_title: Overdose section

message: First ref says "Our findings suggest that methylphenidate may be associated with a number of serious adverse events as well as a large number of non-serious adverse events in children "
Second ref says "the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects."
The text was supported. Doc James (talk · contribs · email) 11:40, 1 November 2019 (UTC)
thread_title:  Text 

message: Ref says "Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm), and individuals may have larger increases... Cardiac: angina, arrhythmia, palpitations, pulse increased or decreased, tachycardia"
Doc James (talk · contribs · email) 10:27, 29 January 2020 (UTC)
thread_title: Cardiovascular disease

message: Support the 2019 proposal to merge to brand Daytrana to the generic name for the drug. Klbrain (talk) 17:34, 18 April 2020 (UTC)
replies: text: Done Doc James (talk · contribs · email) 07:06, 21 May 2020 (UTC)
thread_title:  Merge proposal 

message: I am not able to contribute professional knowledge to this article, but I would like to share some personal experience. Methylphenidate was a psychiatric "magic bullet" for me. After decades of crippling clinical depression, my current psychiatric care provider (the most recent in a series of at least six) suggested it. The improvement in my symptoms was immediate, intense, and lasting. I had run through the gamut of conventional depression treatments prior to this, including ECT, with no relief, and did not know that methylphenidate was an option. I suspect that many of my former providers did not know either, or considered it a last resort.
If someone could expand this section and include some links to academic or medical sources it would be of enormous value to other people who are struggling with treatment-resistant depression. It is difficult as a layman or patient to find information about this use of methylphenidate, and heathcare providers seem to be gun-shy about recommending it. 216.30.159.93 (talk) 23:38, 11 September 2020 (UTC)
thread_title: Use in depression

message: Currently it is: "It is not a Cocaine derivate nor analogue. Cocaine is analgesic and ligand channel blocker with SNDRI action while Methylphenidate is NDRI with 2-3 fold DAT selectivity over NET. Cocaine also more potent in SERT rather than NDRI site. [7]"
But it should be as follows: It is not a Cocaine derivate nor an analog. Cocaine is an analgesic and ligand channel blocker with SNDRI action while Methylphenidate is an NDRI with 2-3 fold DAT selectivity over NET. Cocaine is also more potent in SERT rather than NDRI sites. [7]"
(First time posting on wiki hope I did it right)
:I noticed that too, upon a first reading of the article. I made the corrections that you suggested. Thank you! And yes, you posted correctly here on the talk page!--FeralOink (talk) 12:54, 2 January 2022 (UTC)
thread_title:  Fix grammar here.. 

message: This sentence under Other medical uses, "However, the use of stimulants such as methylphenidate in cases of treatment-resistant depression is controversial.[42]", references a journal article from 1992.
Kraus MF, Burch EA (October 1992). "Methylphenidate hydrochloride as an antidepressant: controversy, case studies, and review". Southern Medical Journal. 85 (10): 985–991. doi:10.1097/00007611-199210000-00012. PMID 1411740
30 years later, it's relatively common to use Methylphenidate to augment other medications in treatment-resistant depression. Therefore, I believe that either this sentence needs to be reevaluated for whether it's necessary, and/or more recent references are needed to back up this claim. Alteredtome (talk) 04:14, 12 April 2022 (UTC)
thread_title:  More recent research needed for this claim 

message: To all who contributed to writing this Article, all I can say is might just be the best article I’ve read on the entire site. Which is thousands so it’s saying a lot for me. Well done. 2601:644:8F83:D7A0:79B2:28C7:ECD2:4397 (talk) 01:08, 1 October 2022 (UTC)
thread_title:  Thanks to all 

message: Firstly this article reads in parts like an advert instead of a normal article on substances. Secondly, the delphic analyis which includes police and legal services is not useful in estimating addictive, deadly, or dangerous potential, rather it can only indicate attitudes instead of expert opinion due to the inclusion of police. Given that the police involved in this study are engaged in a drug war which generally treats pharmaceuticals as arbitrarily less dangerous, it's an obvious bias. This diagramm is misleading and should be deleted as should references to it. 77.188.117.198 (talk) 16:21, 23 January 2023 (UTC)
thread_title:  advert and delphic analysis problem 

message: To me it seems superfluous and it might be found confusing to readers. Gutten på Hemsen (talk) 15:59, 15 April 2023 (UTC)
thread_title:  Why are there two History sections? 

message: From Adverse Effects:
"Ophthalmologic adverse effects may include blurred vision caused by pupil dilatation and dry eyes, with less frequent reports of diplopia and mydriasis"
This seems to be saying that mydriasis is less common than dilated pupils. These terms are synonymous. Is this a syntactical issue I'm missing or is it contradictory?
his seems to be saying that dilated pupils are less common than 2603:7081:1603:A300:2CC4:A198:82DB:C8BF (talk) 02:44, 28 September 2023 (UTC)
thread_title:  Contradiction around mydriasis? 

message: Methylphenidate and MAOIs are perfectly safe to use concomitantly, despite common dogma to the contrary. MPH is not a releaser of norepinephrine unlike DEX and especially mixed AMP salts (due to the presence of levoamphetamines which have strong peripheral effects). There is virtually no risk of precipitating a hypertensive crisis if titrated/managed properly.  The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression and MAOIs and CNS Stimulants 206.194.253.145 (talk) 04:44, 21 January 2024 (UTC)
thread_title:  Methylphenidate and MAOIs - A Safe and Effective Combination  

message: Is there a reason there are two images? Could they be combined and the legend amended accordingly? 90.240.165.192 (talk) 09:13, 15 May 2024 (UTC)
thread_title:  Immediate-release header 

message: In 2024, the European Society for Child and Adolescent Psychiatry (ESCAP) and the American Academy of Child and Adolescent Psychiatry (AACAP) recalled the decision of an Expert Committee under the World Health Organisation (WHO) to recommend against the use of methylphenidate as an essential treatment due to strong doubts about its efficacy relative to placebo. They endorsed the inclusion of methylphenidate in the WHO Essential Medicines List due to its proven track record of short and long-term safety, effectiveness and necessity as an essential treatment for ADHD.
ACCAP recognises that methylphenidate is among the most safe and efficacious drugs in all of paediatrics. Both ESCAP & ACCAP denounce the meta-analysis of RCTs by Storebø and colleagues due to its use of idiosyncratic methods to assess the quality of the evidence and factual errors, a crucial point I and others have established in this talk page.
These recent endorsements, in combination with 51 other professional medical organisations in 2021, and the International Consensus Statement on ADHD, I hope will add to the evidence-base for maintaining the article in its current state; encourage consensus; and prevent any future reliance on such evidently flawed meta-analyses and contradictory WHO interpretation. Димитрий Улянов Иванов (talk) 23:41, 1 June 2024 (UTC)
thread_title:  ESCAP & AACAP endorse the inclusion of methylphenidate in the WHO model list of essential medicines and denounce the meta-analysis of RCTs by Storebø and colleagues